Advances in newborn screening for Pompe disease and resulting clinical outcomes

References

• Hirschhorn R, Reuser A. Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency. In: Scriver C, Beaudet A, Sly W, et al., editors. The metabolic and molecular bases of inherited disease. 8th ed. Vol. III. New York (NY): McGraw-Hill; 2001. p. 3389–3420.
   Google Scholar
• van den Hout HM, Hop W, van Diggelen OP, et al. The natural course of infantile Pompe’s disease: 20 original cases compared with 133 cases from the literature. Pediatrics. 2003;112(2):332–340.
   PubMed Web of Science ®Google Scholar
• Kishnani PS, Hwu WL, Mandel H, et al. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr. 2006;148(5):671–676.
   PubMed Web of Science ®Google Scholar
• Van den Hout H, Reuser AJ, Vulto AG, et al. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet. 2000;356(9227):397–398.
   PubMed Web of Science ®Google Scholar
• Amalfitano A, McVie-Wylie AJ, Hu H, et al. Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase. Proc Natl Acad Sci USA. 1999;96(16):8861–8866.
   PubMed Web of Science ®Google Scholar
• Kishnani PS, Corzo D, Nicolino M, et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology. 2007;68(2):99–109.
   PubMed Web of Science ®Google Scholar
• Nicolino M, Byrne B, Wraith JE, et al. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med Off J Am Coll Med Genet. 2009;11(3):210–219.
   Google Scholar
• Chien YH, Chiang SC, Zhang XK, et al. Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program. Pediatrics. 2008;122(1):e39–e45.
   PubMed Web of Science ®Google Scholar
• Guthrie R. The introduction of newborn screening for phenylketonuria. A personal history. Eur J Pediatr. 1996;155(Suppl 1):S4–S5.
   PubMed Web of Science ®Google Scholar
• Chamoles NA, Blanco M, Gaggioli D, et al. Tay-Sachs and Sandhoff diseases: enzymatic diagnosis in dried blood spots on filter paper: retrospective diagnoses in newborn-screening cards. Clin Chim Acta. 2002;318(1–2):133–137.
   PubMed Web of Science ®Google Scholar
• Chamoles NA, Niizawa G, Blanco M, et al. Glycogen storage disease type II: enzymatic screening in dried blood spots on filter paper. Clin Chim Acta. 2004;347(1–2):97–102.
   PubMed Web of Science ®Google Scholar
• Li Y, Scott CR, Chamoles NA, et al. Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening. Clin Chem. 2004;50(10):1785–1796.
   PubMed Web of Science ®Google Scholar
• Zhang H, Kallwass H, Young SP, et al. Comparison of maltose and acarbose as inhibitors of maltase-glucoamylase activity in assaying acid alpha-glucosidase activity in dried blood spots for the diagnosis of infantile Pompe disease. Genet Med. 2006;8(5):302–306.
   PubMed Web of Science ®Google Scholar
• Umapathysivam K, Whittle AM, Ranieri E, et al. Determination of acid alpha-glucosidase protein: evaluation as a screening marker for Pompe disease and other lysosomal storage disorders. Clin Chem. 2000;46(9):1318–1325.
   PubMed Web of Science ®Google Scholar
• Umapathysivam K, Hopwood JJ, Meikle PJ. Determination of acid alpha-glucosidase activity in blood spots as a diagnostic test for Pompe disease. Clin Chem. 2001;47(8):1378–1383.
   PubMed Web of Science ®Google Scholar
• Sista RS, Eckhardt AE, Wang T, et al. Digital microfluidic platform for multiplexing enzyme assays: implications for lysosomal storage disease screening in newborns. Clin Chem. 2011;57(10):1444–1451.
   PubMed Web of Science ®Google Scholar
• Spacil Z, Tatipaka H, Barcenas M, et al. High-throughput assay of 9 lysosomal enzymes for newborn screening. Clin Chem. 2013;59(3):502–511.
   PubMed Web of Science ®Google Scholar
• Gelb MH, Scott CR, Turecek F. Newborn screening for lysosomal storage diseases. Clin Chem. 2015;61(2):335–346.
   PubMed Web of Science ®Google Scholar
• Labrousse P, Chien YH, Pomponio RJ, et al. Genetic heterozygosity and pseudodeficiency in the Pompe disease newborn screening pilot program. Mol Genet Metab. 2010;99(4):379–383.
   PubMed Web of Science ®Google Scholar
• Tajima Y, Matsuzawa F, Aikawa S, et al. Structural and biochemical studies on Pompe disease and a “pseudodeficiency of acid alpha-glucosidase”. J Hum Genet. 2007;52(11):898–906.
   PubMed Web of Science ®Google Scholar
• Kroos MA, Mullaart RA, Van Vliet L, et al. p.[G576S; E689K]: pathogenic combination or polymorphism in Pompe disease? Eur J Hum Genet. 2008;16(8):875–879.
   PubMed Web of Science ®Google Scholar
• Chien YH, Hwu WL, Lee NC. Pompe disease: early diagnosis and early treatment make a difference. Pediatr Neonatol. 2013;54(4):219–227.
   PubMed Web of Science ®Google Scholar
• Yang CC, Chien YH, Lee NC, et al. Rapid progressive course of later-onset Pompe disease in Chinese patients. Mol Genet Metab. 2011;104(3):284–288.
   PubMed Web of Science ®Google Scholar
• Chiang SC, Hwu WL, Lee NC, et al. Algorithm for Pompe disease newborn screening: results from the Taiwan screening program. Mol Genet Metab. 2012;106(3):281–286.
   PubMed Web of Science ®Google Scholar
• Shigeto S, Katafuchi T, Okada Y, et al. Improved assay for differential diagnosis between Pompe disease and acid alpha-glucosidase pseudodeficiency on dried blood spots. Mol Genet Metab. 2011;103(1):12–17.
   PubMed Web of Science ®Google Scholar
• Oda E, Tanaka T, Migita O, et al. Newborn screening for Pompe disease in Japan. Mol Genet Metab. 2011;104(4):560–565.
   PubMed Web of Science ®Google Scholar
• Chien YH, Lee NC, Thurberg BL, et al. Pompe disease in infants: improving the prognosis by newborn screening and early treatment. Pediatrics. 2009;124(6):e1116–e1125.
   PubMed Web of Science ®Google Scholar
• An Y, Young SP, Kishnani PS, et al. Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease. Mol Genet Metab. 2005;85(4):247–254.
   PubMed Web of Science ®Google Scholar
• Manwaring V, Prunty H, Bainbridge K, et al. Urine analysis of glucose tetrasaccharide by HPLC: a useful marker for the investigation of patients with Pompe and other glycogen storage diseases. J Inherit Metab Dis. 2012;35(2):311–316.
   PubMed Web of Science ®Google Scholar
• Chien YH, Goldstein JL, Hwu WL, et al. Baseline urinary glucose tetrasaccharide concentrations in patients with infantile- and late-onset Pompe disease identified by newborn screening. JIMD Rep. 2015;19:67–73.
   PubMedGoogle Scholar
• Yang CF, Liu HC, Hsu TR, et al. A large-scale nationwide newborn screening program for Pompe disease in Taiwan: towards effective diagnosis and treatment. Am J Med Genet A. 2014;164A(1):54–61.
   PubMed Web of Science ®Google Scholar
• Mechtler TP, Stary S, Metz TF, et al. Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria. Lancet. 2012;379(9813):335–341.
   PubMed Web of Science ®Google Scholar
• Wittmann J, Karg E, Turi S, et al. Newborn screening for lysosomal storage disorders in Hungary. JIMD Rep. 2012;6:117–125.
   PubMedGoogle Scholar
• Hopkins PV, Campbell C, Klug T, et al. Lysosomal storage disorder screening implementation: findings from the first six months of full population pilot testing in Missouri. J Pediatr. 2015;166(1):172–177.
   PubMed Web of Science ®Google Scholar
• Scott CR, Elliott S, Buroker N, et al. Identification of infants at risk for developing Fabry, Pompe, or mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry. J Pediatr. 2013;163(2):498–503.
   PubMed Web of Science ®Google Scholar
• Matern D, Gavrilov D, Oglesbee D, et al. Newborn screening for lysosomal storage disorders. Semin Perinatol. 2015;39(3):206–216.
   PubMed Web of Science ®Google Scholar
• Kishnani PS, Corzo D, Leslie ND, et al. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res. 2009;66(3):329–335.
   PubMed Web of Science ®Google Scholar
• Chen LR, Chen CA, Chiu SN, et al. Reversal of cardiac dysfunction after enzyme replacement in patients with infantile-onset Pompe disease. J Pediatr. 2009;155(2):271–275 e272.
   PubMed Web of Science ®Google Scholar
• Chien YH, Lee NC, Chen CA, et al. Long-term prognosis of patients with infantile-onset Pompe disease diagnosed by newborn screening and treated since birth. J Pediatr. 2015;166(4):985-991 e981–982.
   PubMed Web of Science ®Google Scholar
• Chien YH, Lee NC, Peng SF, et al. Brain development in infantile-onset Pompe disease treated by enzyme replacement therapy. Pediatr Res. 2006;60(3):349–352.
   PubMed Web of Science ®Google Scholar
• Ebbink BJ, Aarsen FK, Van Gelder CM, et al. Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy. Neurology. 2012;78(19):1512–1518.
   PubMed Web of Science ®Google Scholar
• Amalfitano A, Bengur AR, Morse RP, et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med. 2001;3(2):132–138.
   PubMed Web of Science ®Google Scholar
• Kishnani PS, Goldenberg PC, DeArmey SL, et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab. 2010;99(1):26–33.
   PubMed Web of Science ®Google Scholar
• Messinger YH, Mendelsohn NJ, Rhead W, et al. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med. 2012;14(1):135–142.
   PubMed Web of Science ®Google Scholar
• Broomfield A, Davison J, Fletcher J, et al. The UK experience of enzyme replacement therapy in patients with infantile onset Pompe disease. Mol Genet Metab. 2015;114(2):S24–S25.
   Web of Science ®Google Scholar
• Gungor D, Reuser AJ. How to describe the clinical spectrum in Pompe disease? Am J Med Genet A. 2013;161A(2):399–400.
   PubMed Web of Science ®Google Scholar
• Byrne BJ, Kishnani PS, Case LE, et al. Pompe disease: design, methodology, and early findings from the Pompe registry. Mol Genet Metab. 2011;103(1):1–11.
   PubMed Web of Science ®Google Scholar
• Lee DH, Qiu WJ, Lee J, et al. Hypertrophic cardiomyopathy in pompe disease is not limited to the classic infantile-onset phenotype. JIMD Rep. 2014;17:71–75.
   PubMedGoogle Scholar
• Chien YH, Lee NC, Huang HJ, et al. Later-onset Pompe disease: early detection and early treatment initiation enabled by newborn screening. J Pediatr. 2011 Jun;158(6):1023–1027 e1021.
   PubMed Web of Science ®Google Scholar
• Feeney EJ, Austin S, Chien YH, et al. The value of muscle biopsies in Pompe disease: identifying lipofuscin inclusions in juvenile- and adult-onset patients. Acta Neuropathol Commun. 2014;2:2.
   PubMedGoogle Scholar
• Chien YH, Lee NC, Huang PH, et al. Early pathologic changes and responses to treatment in patients with later-onset Pompe disease. Pediatr Neurol. 2012;46(3):168–171.
   PubMed Web of Science ®Google Scholar
• Raben N, Ralston E, Chien YH, et al. Differences in the predominance of lysosomal and autophagic pathologies between infants and adults with Pompe disease: implications for therapy. Mol Genet Metab. 2010;101(4):324–331.
   PubMed Web of Science ®Google Scholar
• Carlier RY, Laforet P, Wary C, et al. Whole-body muscle MRI in 20 patients suffering from late onset Pompe disease: involvement patterns. Neuromuscul Disord. 2011;21(11):791–799.
   PubMed Web of Science ®Google Scholar
• Horvath JJ, Austin SL, Case LE, et al. Correlation between quantitative whole-body muscle magnetic resonance imaging and clinical muscle weakness in Pompe disease. Muscle Nerve. 2015;51(5):722–730.
   PubMed Web of Science ®Google Scholar
• Cupler EJ, Berger KI, Leshner RT, et al. Consensus treatment recommendations for late-onset Pompe disease. Muscle & Nerve. 2012;45(3):319–333.
   PubMed Web of Science ®Google Scholar
• Weinreich SS, Rigter T, Van El CG, et al. Public support for neonatal screening for Pompe disease, a broad-phenotype condition. Orphanet J Rare Dis. 2012;7:15.
   PubMed Web of Science ®Google Scholar
• Van El CG, Rigter T, Reuser AJ, et al. Newborn screening for Pompe disease? a qualitative study exploring professional views. BMC Pediatr. 2014;14:203.
   PubMed Web of Science ®Google Scholar
• Kwon JM, Steiner RD. “I’m fine; I’m just waiting for my disease”: the new and growing class of presymptomatic patients. Neurology. 2011;77(6):522–523.
   PubMed Web of Science ®Google Scholar
• Timmermans S, Buchbinder M. Patients-in-waiting: living between sickness and health in the genomics era. J Health Soc Behav. 2010;51(4):408–423.
   PubMed Web of Science ®Google Scholar
• Rigter T, Weinreich SS, van El CG, et al. Severely impaired health status at diagnosis of Pompe disease: a cross-sectional analysis to explore the potential utility of neonatal screening. Mol Genet Metab. 2012;107(3):448–455.
   PubMed Web of Science ®Google Scholar
• Gurian EA, Kinnamon DD, Henry JJ, et al. Expanded newborn screening for biochemical disorders: the effect of a false-positive result. Pediatrics. 2006;117(6):1915–1921.
   PubMed Web of Science ®Google Scholar
• Hewlett J, Waisbren SE. A review of the psychosocial effects of false-positive results on parents and current communication practices in newborn screening. J Inherit Metab Dis. 2006;29(5):677–682.
   PubMed Web of Science ®Google Scholar
• Van Gelder CM, Van Capelle CI, Ebbink BJ, et al. Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy. J Inherit Metab Dis. 2012;35(3):505–511.
   PubMed Web of Science ®Google Scholar
• Prater SN, Banugaria SG, DeArmey SM, et al. The emerging phenotype of long-term survivors with infantile Pompe disease. Genet Med. 2012;14(9):800–810.
   PubMed Web of Science ®Google Scholar
• Jones HN, Muller CW, Lin M, et al. Oropharyngeal dysphagia in infants and children with infantile Pompe disease. Dysphagia. 2010;25(4):277–283.
   PubMed Web of Science ®Google Scholar
• Case LE, Bjartmar C, Morgan C, et al. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease. Neuromuscular Disorders: NMD. 2015;25(4):321–332.
   PubMed Web of Science ®Google Scholar
• Jones HN, Crisp KD, Moss T, et al. Effects of respiratory muscle training (RMT) in children with infantile-onset Pompe disease and respiratory muscle weakness. J Pediatr Rehabil Med. 2014;7(3):255–265.
   PubMedGoogle Scholar
• Lim JA, Li L, Raben N. Pompe disease: from pathophysiology to therapy and back again. Front Aging Neurosci. 2014;6:177.
   PubMed Web of Science ®Google Scholar